Date:13 September 2023

provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

Grants or contracts from any entity (if not indicated in item

#1 above).

Royalties or licenses

Consulting fees

Your Name: MARTA JAT BATISTA

Manuscript Title:Preclinical ar insighr on central nervous sys Manuscript number (if known	tem activity	umab-deruxtecan in breast cancer brain metastases: a new
related to the content of your parties whose interests may be	manuscript. "Related" mean be affected by the content of necessarily indicate a bias.	elationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a
The following questions apply manuscript only.	to the author's relationship	s/activities/interests as they relate to the <u>current</u>
	tension, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
In item #1 below, report all su the time frame for disclosure		in this manuscript without time limit. For all other items,
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
-	Tiroe frame: Sloce the initia	d planning of the work
All support for the present manuscript (e.g., funding,	<u>以</u> None	

Time frame: past 36 mooths

∠None

None

∠None

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	GSK	1
		Novaens Daichi Saningo	
6	Payment for expert testimony	<u> ✓ None</u>	
7	Support for attending meetings and/or travel	None	
	<b>G</b> 7.7	PATIENT SANKYO NOVARING	
		ASTRA ZOUCCA	
8	Patents planned, issued or pending	None	
9	Participation on a Data	None	
	Safety Monitoring Board or	ASTRIA ZENEUA	
	Advisory Board	9ALICHI SANHO	
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid	ESNO	
11	Stock or stock options	✓ None	
12	Receipt of equipment, materials, drugs, medical	<u>&amp;_</u> None	
	writing, gifts or other services		
13	Other financial or non- financial interests	<u>⊀</u> None	

	GSK, NOVARIUS AND DATICKI SANKYO
TOWEL SUPPORT	FIG. 1 DATICHI - SANIGIO, NOVARITIS AND ASTMA ZENZUA
Leadership nisk	
cesaring war	

Please place an "X" next to the following statement to indicate your agreement:

Date:13	Septem	her 2	023
Dutc. 10	SCPECII	IDCI 2	.020

Your Name: JOSE MANUEL PEREZ GARCIA

Manuscript Title:Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insighr on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	I 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u></u> ✓ None	
3	Royalties or licenses	<u></u> ✓ None	
4	Consulting fees	None	
		ASMA ZENECA, GILEAD	
		SEATTLE CENETICS ROCHE, ASD	

Eisai, DAILCH: SANNYO, LILLY

5	Payment or honoraria for	<u></u> ∧ None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	<u></u> None	
7	Support for attending meetings and/or travel	None	
		ROCHE	
8	Patents planned, issued or pending	<u>∝</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	× None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u></u> None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>√</u> None	
13	Other financial or non- financial interests	✓ None	

HONORARIA: ASTRA ZENECA, GILEAD, SEA TILE GENETICS, ROCHE, OSD, EISA; DATICHI SANTRYO,
Lilly
TOLANEL GRANT: ROCHE

Please place an "X" next to the following statement to indicate your agreement:

Date:13	Septem	ber	2023
---------	--------	-----	------

Your Name: INES FERNANDES EIRIZ

Manuscript Title:Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insighr on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
	Grants or contracts from any entity (if not indicated in item #1 above).	_≾_None	
3	Royalties or licenses	<u></u> ✓_None	
4	Consulting fees	<u>✓</u> None	

Payment or honoraria for	None	
lectures, presentations, speakers bureaus, manuscript writing or educational events	NOVARTIS	
Payment for expert testimony	None	
Support for attending meetings and/or travel	None	
	DANIGHI SANIGO	
Patents planned, issued or pending	× None	
Participation on a Data	× None	
Safety Monitoring Board or Advisory Board		
Leadership or fiduciary role in other board, society, committee or advocacy	<u>x</u> _None	
Stock or stock options		
materials, drugs, medical writing, gifts or other	None	
Other financial or non- financial interests	<u> </u>	
	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-  None

HONORARIA: NOVARTIS		
TRAVEL SUPPORT, PALICHI	SANIGO	

Please place an "X" next to the following statement to indicate your agreement:

Date:13 September 2023			
Your Name: MAMA GON			
Service of the servic			

Manuscript Title:Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insighr on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Sloce the loftfa	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	<u></u> ✓ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None	
		ASTRA ZETUEZA	
		GLEA9	
		NOVARIO	
	educational events		
6	Payment for expert testimony	×_None	
7	Support for attending meetings and/or travel	None	
		ROCHE	
		Phi ter	
8	Patents planned, issued or pending	None	
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board	Great	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	×_None	
11	Stock or stock options	None	
	D	N	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_x_None	
13	Other financial or non- financial interests	<u>&gt; None</u>	

HONDMANA: ASTRA ZOVERA, GILLAD, NOVAR	ZM
TRAVEL SUPPORT; ROCHE, PRIZER	
ADVIORY BOARD: GILERD	

Please place an "X" next to the following statement to indicate your agreement:

Date:13	Septem	ber 2023
---------	--------	----------

Your Name: ANTONIO LLOWBART

Manuscript Title:Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insighr on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Siece the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 morrhs
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>w</u> None	
3	Royalties or licenses	<u></u> ✓ None	
4	Consulting fees	<u>≪</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
		LILLY ASTOR ZONECA	
		DEDCK DIANGE SHORE	
6	Payment for expert testimony	_x_None	
7	Support for attending meetings and/or travel	None	
	miceange anayor dove	ROCHE RECEC	
		ANTICA ZONECA	Propagation of the Control of the Co
8	Patents planned, issued or pending	<u>×</u> None	
9	Participation on a Data	None	
	Safety Monitoring Board or	LILLY, POCHE	
	Advisory Board	PRACE NOVAGE	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
		DAJ CAPITAL E INVITA RESEARCH	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-	None	
	financial interests	RESERVEN SUPPORT: POLICE	
	<u> </u>	NOVANTY, ASD, GLEAD,	

HONDRANA: Lily, ASTRA ZENECA, NERK SHARP & DHONE
TRAVEL SUPPORT. ROCHE, PRITUR, NITHA ZENECA
ADVISORY BOARD: CILLY, ROCHE, RESTOR, NOVARRU

STOCK: NAJ CARTAL & INTIA RESERVOR
RESTARCE SUPPORT. ROCHE, AGENZIA, LILLY, PRITER, NOVARTIE, NSD, GILEAD, DAVICHI LAMOGO

Please place an "X" next to the following statement to indicate your agreement:

Date:13 September 2023

Your Name: SOFA BRAGA

Manuscript Title:Preclinical and clinical efficacy of Trastuzumab-deruxtecan in breast cancer brain metastases: a new insighr on central nervous system activity

Manuscript number (if known): ATM-23-1603

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Yime frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u></u> X None	
3	Royalties or licenses	<u>以</u> None	
4	Consulting fees	None  DAIICHI SANIAYO  ASTRA ZENECA	COMPANY PAYMENTS

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
		DATION: SANGO	COMPANY PAYTENTY
		A STAR HOUTCA	-CORPANY PAYMENUTS
6	Payment for expert testimony	× None	
7	Support for attending meetings and/or travel	None	
		DATIONI SANAYO	COLPANY PAYNENTS
		ASTON PENELA	COMPANY PAYAENTS
8	Patents planned, issued or pending	<u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u>	
11	Stock or stock options	<u>&gt;</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>×</u> None	
13	Other financial or non- financial interests	<u>&gt;</u> None	

CONSULTING FEES: DATICHI SANKYO, ASTRA ZENECA	
MONDRACIA: PRINCHI SANKYO, ASTARA ZENECA	
TOLANEL CHANTS: DATICHI SHUTEYO, ASTRA PENECIA	

Please place an "X" next to the following statement to indicate your agreement:

	e:13 September 2023	-56-	
		NTES	
		1/2:	ımab-deruxtecan in breast cancer brain metastases: a new
	ighr on central nervous syste	televit of the reference of the first	
Ma	nuscript number (if known):	ATM-23-1603	
rela par to t rela	ated to the content of your matter whose interests may be transparency and does not not ationship/activity/interest, it is following questions apply to	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do s	elationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a o.
ma	<u>nuscript only</u> .		
to t	the epidemiology of hyperte dication, even if that medica	nsion, you should declare a ation is not mentioned in th port for the work reported	efined broadly. For example, if your manuscript pertains Il relationships with manufacturers of antihypertensive e manuscript. in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	
1			institution)
		none (add rows as needed)	institution)
			100 sold sold sold 100 to 100
1	All support for the present	none (add rows as needed)	100 sold sold sold 100 to 100
1	manuscript (e.g., funding,	none (add rows as needed) Time frame: Since the initial	100 sold sold sold 100 to 100
1	manuscript (e.g., funding, provision of study materials,	none (add rows as needed) Time frame: Since the initial	100 sold sold sold 100 to 100
1	manuscript (e.g., funding, provision of study materials, medical writing, article	none (add rows as needed) Time frame: Since the initial	100 sold sold sold 100 to 100
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initial	100 sold sold sold 100 to 100
1	manuscript (e.g., funding, provision of study materials, medical writing, article	none (add rows as needed) Time frame: Since the initial	100 sold sold sold 100 to 100
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initial	100 sold sold sold 100 to 100
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initial	100 sold sold sold 100 to 100
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed)  Time frame: Since the initial  X_None	plansing of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initial	plansing of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed)  Time frame: Since the initial  X_None	plansing of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	none (add rows as needed) Time frame: Since the initial  None  Time frame: past	plansing of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any	none (add rows as needed) Time frame: Since the initial  None  Time frame: past	plansing of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	none (add rows as needed)  Time frame: Since the initial  None  Time frame: past  None	plansing of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item	none (add rows as needed) Time frame: Since the initial  None  Time frame: past	plansing of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	none (add rows as needed)  Time frame: Since the initial  None  Time frame: past  None	plansing of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	none (add rows as needed)  Time frame: Since the initial  None  Time frame: past  None	plansing of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	none (add rows as needed)  Time frame: Since the initial  None  Time frame: past  None  None	plansing of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	none (add rows as needed)  Time frame: Since the initial  X_None  Time frame: past  X_None  None  None	plansing of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses  Consulting fees	none (add rows as needed)  Time frame: Since the initial  None  Time frame: past  None  None  None  None  None  None	plansing of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses  Consulting fees	none (add rows as needed)  Time frame: Since the Initial  X_None  Itime frame: past  X_None  None  None  None  None  ASMA TENECA SEATTLE  GENETICS, DATICH: SANWYO,	sianning of the work  So months
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses  Consulting fees	none (add rows as needed)  Time frame: Since the initial  None  Time frame: past  None  None  None  None  None  None	sianning of the work  36 months

LILLY, NERK SHAPPE DAMAGES,
LEUKO, BIOASIS, CLOVIS ONCOLOGY
BOCHENGER TWO ELHEIR, ELLIPSES,
HIBERLEU, BIO'NVENT, GENDAB, GILTAD,
NEWARIN, ZYMEMAKS, REVEAL GENDAICS,
EX PRESSION BIOTECHADISTED

Support for attending meetings and/or travel   Support for attending meeting support	5	Payment or honoraria for	None	
Speakers bureaus, manuscrit writing or citius, flooring parts produce, educational events  Payment for expert testimony  Support for attending None  Support for attending None  Recting and/or travel  Support for attending None  Recting and/or travel  R			POLILI NOVAMOS, CILLERA	Ę,
manuscript writing or educational events		speakers bureaus,		
None   Support for attending   None		manuscript writing or	1-11 ADMIC CHARPA PENNE	
Support for attending   None			DAVICK SANIVA ASTOLA TO	uZA
Testimony    Support for attending   None	6		None	
meetings and/or travel    Dicks	U	I THE THE PARTY OF	<u>_x_</u> None	
Patents planned, issued or pending Patents planned, issued or Rubanccuttual Corgination of the Rubanccuttual Corgination of the Rubanccuttual Corgination of the Rubanccuttual Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-financial interests  2 Research Couples to Cossistanous Rubanccuttus, Natura Rubanccuttus, Rubanc	7		None	
Patents planned, issued or pending  Patents planned, issued or Patents planned, issued planned, issued planned, issued planned, issued,		meetings and/or traver		
Pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Response of equipment, materials, drugs, medical writing, gifts or other services  The participation on a Data  None  Response of the participation of the partic			PALCH SANDO ASTRA LENECA, GICEAS	
Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advoacy group, paid or unpaid  11 Stock or stock options  None  ROSAL NEWTOM PHARMCOUNTS  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-financial interests  14 None  None  None  RESEARCH ROSALE TO COSTILLION RECEIPTIONS (MARMCOUNTS), NOTA ZUNCA, CANTRE COSTILLION RECEIPTIONS, NOTA ZUNCA, CANTRE COSTILLION RECEIPTIONS, NOTA ZUNCA, CANTRE COSTILLION, NOTA	8	Patents planned, issued or	None	
9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- financial interests  Paralle Anglando to Colonia Anglando to Colonia Fall (Anglando to Colonia)  None  None  None  None  None  None  None  Paralle Anglando to Colonia Anglando to Colonia Fall (Anglando to Colonia)  None  Persente Anglando to Colonia Anglando to Colonia Fall (Anglando to Colonia)  None  None  None  None  None  None  None  None  Persente Anglando to Colonia Fall (Anglando to Colonia)  None  Persente Anglando to Colonia Fall (Anglando to Colonia)  None  Persente Anglando to Colonia Fall (Anglando to Colonia)  None  Persente Anglando to Colonia Fall (Anglando to Colonia)  Persente Anglando to Colonia Fall (Anglando to Colonia)  None  Colonia Fall (Anglando to Colonia)  Colonia Fall (Anglando to Colonia)  Colonia Fall (Anglando to Colonia)  None  Colonia Fall (Anglando to Colonia)  Persente Anglando to Colonia Fall (Anglando to Colonia)  None  Colonia Fall (Anglando to Colonia)  Receipt of equipment, Mala (Anglando to Colonia)  Receipt of explando to Colonia Fall (Anglando to Colonia)  Receipt of explando to Colonia Fall (Anglando to Colonia)  None  None		pending		
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  None  12 Receipt of equipment, Mone  13 Stock or stock options  None  14 Stock or stock options  None  15 Stock or stock options  None  16 Stock or stock options  None  16 Stock or stock options  None  17 Stock or stock options  None  18 Other financial or non- financial interests  None  None  18 Other financial or non- financial interests  None  None  19 Stock or stock options  None  1			PILSCA WHISTOR AND A CYTCHOT	BULL DATUSTING YOUTH
Safety Monitoring Board or Advisory Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  None  12 Receipt of equipment,	9	Participation on a Data	» None	
Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-financial interests  14 Other financial interests  15 Other financial interests  16 Other financial interests  17 Other financial interests  18 Other financial interests  19 Other financial interests  19 Other financial interests  10 Other financial interests  10 Other financial interests  11 Other financial interests  12 Other financial interests  13 Other financial interests  14 Other financial interests  15 Other financial interests  16 Other financial interests  17 Other financial interests  18 Other financial interests  18 Other financial interests  19 Other financial interests  10 Other financial interests  11 Other financial interests  12 Other financial interests  13 Other financial interests  14 Other financial interests  15 Other financial interests  16 Other financial interests  16 Other financial interests  17 Other financial interests  18 Other financial inte			7	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-financial interests  255 ALLE STANLE RUSHIES TO CHARLES BURNET FRANCE THE FRANK CA TSCHE A				
in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  None  (Response for the printing printing)  Life to (ALLANIC)  Life to (ALLANIC)  Life to (ALLANIC)  None  (Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-financial interests  Response for the printing for	10		× None	
Committee or advocacy group, paid or unpaid  11 Stock or stock options  None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- financial interests  Parathacondulas and Parathacondulas  Reseptive flavore for colonia and Parathacondulas  Reseptive flavore flavor	10	1	None	
group, paid or unpaid  11 Stock or stock options  None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- financial interests  None  None  PESSERGEU PROPOSE TO CUSTONION. PECHE, PARA PHARMACEUTIUS, ANTHA ZUNCA, BANATA, CANGUSTANIA ARTHANIA, PANAMACEUTIUS, ANTHA ZUNCA, PLEASE SUMMARIZE THE above conflict of interest in the following box:  CONSDITING: ROCKE, CONGUS, CELLISTIA, ASSIA ZENCA, SEATTLE GENETIC, SPACE, COURTE, ATHENEX, GUYP LING, ISS, SEX, CELURO BOASS, CONGUSTANIA, SEATTLE GENETIC, SPACE, COURTE, ATHENEX, GUYP LING, ISS, SEX, CELURO BOASS, CONGUSTANIA, SEATTLE GENETIC, SPACE, COURTE, ATHENEX, GUYP LINGANIA: LECKE, NOMEONS, CELESTIC, ESSA, PARAMA ZENCEA, SEATTLE GENETIC, SPACE, COURTE, ATHENEX, GUYP HAMBANA: LECKE, NOMEONS, CELESTIC, ESSA, PARAMACEUTICAL CONSINTION OF A PICKSA INHIBITION AND A RICAGNOSTIC SPACE, SEATTLE CONTROL SPACE, SEATTLE CONTROL SPACE, CELESTIC  PARAMACEUTICAL CONSINTION OF A PICKSA INHIBITION AND A RICAGNOSTIC SPACE OF GITOTOXIC TERM RESEARCH FUNDAMACEUTICAL CONSINTION OF A PICKSA INHIBITION AND A RICAGNOSTIC SPACE OF GITOTOXIC TERM RESEARCH FUNDAMACEUTICAL CONSINTION OF A PICKSA INHIBITION AND A RICAGNOSTIC SPACE OF GITOTOXIC TERM RESEARCH FUNDAMACEUTICAD, LECKE, MARIZE ORGANIA, SARAATA, CANGUS, SARAATA, CANGUS, CONTROL SCAPE, CONTROL SCAPE, CONTROL C				
Stock or stock options  None  THE STANDARD PHARMACUTALS  LEW LO (RELATIVE)  LEW LO (RELATIVE)  LEW LO (RELATIVE)  LEW LO (RELATIVE)  A None  The services  Other financial or non- financial interests  RESEARCH FRANCE TO COSTITUTION RELACIONARY PHARMACUTARS, NOTHAR RENECA, EMALTA CARRYSTATICA AFFAIRS, BAYER, EDIN, FREEMAN LA ROCKE, CARRODATA, INSP  Please summarize the above conflict of interest in the following box:  CONSULTING: ROCK, COSTITUTION, ATTAR PETPLEAN, SCRITTIC GENETICS, PRICE TANGENT, AFAIR LATE  CONSULTING: ROCK, COSTITUTION, ATTAR PETPLEAN, SCRITTIC GENETICS, PRICE TANGENT, AFAIR LATE  CONSULTING: ROCK, COSTITUTION, ATTAR PETPLEAN, SCRITTIC GENETICS, PRICE TANGENT, AFAIR LATE  CONSULTING: ROCK, COSTITUTION, CLICATOR, ATTAR PETPLEAN, SCRITTIC GENETICS, SHICK TANGENT, ATTAR PETPLEAN, SCRITTIC GENETICS, SHICK TANGENT, ATTAR PETPLEAN, SCRITTIC GENETICS, SHICK TANGENT, ATTAR PETPLEAN, SCRITTIC GENETICS, CLICATOR, STANDARD, CLICATOR, ATTAR PETPLEAN, SCRITTIC GENETICS, CLICATOR, ATTAR PETPLEAN, STANDARD, CLICATOR, ATTAR PETPLEAN, PARTICA CORS, CLICA, TOD, PARTICAL COMPARTION OF A PIXELA NATION AND A THEORY, OF LEAD  PARTICIS PRACECUTICAL COMPARTION OF A PIXELA NATION OF A PIXELA NATIONARY AND A THEORY OF STANDARD COMPARTION OF A PIXELA NATIONARY OF STANDARD COMPARTION OF STANDARD COMPARTION OF A PIXELA NATIONARY OF STANDARD COMPARTION OF STA				
Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- financial interests  RESEARCH FINANCE TO COSTITUTION TRUME, MARIACCUTICAS, ANTIA RUNCA  BARACTA CARRYSTANIA REGIONAL CARROLL FRANCE OF COSTITUTION TRUME, AND RESEARCH FINANCE TO COSTITUTION TRUME, AND RESEARCH FINANCE OF COSTITUTION TRUME, AND RESEARCH FINANCE OF COSTITUTION, ANTIA RUNCA  Please summarize the above conflict of interest in the following box:  CONSULTING: ROCKE, COSTITUTION, ANTIA PENECA, SEATTH GENETICS SMICH: SAMPLE, CONTINUE, ATTHEWAY, ARE RES.  COSTITUTO; SEAK, COUNCE, BOASS, CLOW BOASS, CLOW BOASS, COSTITUTION, ANTIA CONTINUE, SAMPLE, COUNCE, CONTINUE, FINANCE, CONTINUE, ANTIA CONTINUE, CONTINUE, ANTIA CONTINUE, CONTINUE, ANTIA C		C CARGO CONTRACTOR CON		
Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- financial interests  None  None  RESERVE FRANCE TO CRISTIANON REMEMBERS FRANCECUTIONS, ATTER ZENECA, BANALTA CONSYSTICA AFFACTO, BAYER, EDAY, FRANCECUTIONS, ATTER ZENECA, BANALTA CONSYSTICA AFFACTO, BAYER, EDAY, FRANCECUTIONS, ATTER ZENECA, BANALTA CONSYSTICA AFFACTO, BAYER, EDAY, FRANCE CONTROL AFFACTO, SOUTH TO DUAL MELL SLOCKARC IN THE ABSENCE OF CLIPOTOXIC THERAPY, ARE REAL AND Please summarize the above conflict of interest in the following box:  CONSULTING: ROCKE, CAGULLE, CELLISTIA, ASTAM ZENECA, SENTEL GENETICS, PANICH, SANKER, CAUTHER, ATHERDEX, ROLP, LILY, NSD, BEK, LEUKO, BOASIS, CON ONCOLOGY, BOLPHANICE TROPLISM, EKENTS, HIS CALL, BOAND  KOLDSANA: ROCKE, CAGULLE, CELLISTIA, ASTAM ZENECA, SENTEL GENETICS, PANICH SANKERO, COLUMN, MELLISTIA, EKENTS, HIS CALL, BOAND  LICANSANA: ROCKE, CAGULLE, CELLISTIA, ASTAM ZENECA, SENTEL GENETICS, PANICH SANKERO, COLUMN, MELLISTIA, EKENTS, HIS CALL, BOAND  KOLDSANANA: ROCKE, CAGULLE, CELLISTIA, ASTAM ZUNCIA, SANDONIO SICOLOSIS, LICLY, NSD, ONICHI SANDERO, ASTAM ZUNCIA  PRANCE: BOLKE, NOTARTIS, EISA, ROCKI, ASTAM ZUNCIA, PANICH SANDERO, CHIEADE  PRANCE: PANALOPOL TO LOCAL CARRINATION OF A PICKSCA INHIBITION AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKSCA INHIBITION AND ANICAR TOWN OF A PICKSCA INHIBITION AND AND A NICAR TOWN OF A PICKS	11	Stock or stock options		
Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- financial interests  RESEARCH RUSHIG TO COUNTINGOU TOUGHE, MIRAD PHARMACCUTICAS, NITHA ZUNCA, BARATA, CHRYSTEINE ARTHUR, BAYER, EDIN, FREMAN CA TOUGHE, CURSONAM, DSD  WHER CONTILASTRIP ARTHURO CLUS GENEVEZ, WOLFTA SCHUA CHI FALDE, NO ZOILI 1992 4 A TISEED  422 AS A PREPUTOR OF LESSANGE TO DIAL MERZ BLOCKARE IN THE ABSENCE OF CY TO TOUC THEMAY, ARIZ PART AND  Please summarize the above conflict of interest in the following box:  CONSULTING: ROCKE, CURSULE, CELLISTIA, ASTAN ZENECA, SCATTLE GENETICS, PANICH: STANKYO, CRUTHE, ATHEREX, ROLP, CHUSH, NSD, SEK, LEUKO, BOASS, CLON ON-CAUGH, BOLPHINGE TOUGHLAM, ELEPIC, HIRACHE, ATHEREX, ROLP, CHUSH, NSD, SEK, LEUKO, BOASS, CLON ON-CAUGH, BOLPHINGE TOUGHLAM, ELEPIC, HIRACHE, SOTHER  CHUSHARA: ROCKE, ADVANTO, CELESTIC, ETSA, PRITIS, SANDHONE SICCESS, CICLY, BOD, PANICH: STANKYO, ATHER SENT CLA  TRAVEL: BOLK, NOTHERS, EISA, PRITIS, ASTAN ZUNCLA, PANICH STANKYO, ON LEAD  PROTISTS: PHARMACEUTICAL CARENATION OF A PINSCA INHIBITION AND A LICANOBUS DETABLISHOE AGAIN, FUNCLA  ALICANO LINE GENERAL, NORKE TO PUAL HOLZ BLOCKARO IN THE ABSENCE OF LITTOTICE FROM PRANTEURICAL CARENATIONS OF LINES (STANKYO, CHUSHA)  STOLK: NEDSIR, NEKTHERMANACUNCAN LEUKO (RELATIE)  STOLK: NEDSIR, NEKTHERMANACUNCAN LEUKO (RELATIE)  STOLK: NEDSIR, NEKTHERMANACUNCAN LEUKO (RELATIE)  PLEASE AGAING TO LASTITUTEUR COMMENT MARMATICAL ASTANACA, BARALTA, GABRITAMORA, BARALTA, GABRITAMORA, BARALTA, GABRITAMORA, BARALTA,			HEUSTA, NEWTON PHONE	WANY
materials, drugs, medical writing, gifts or other services  13 Other financial or non-financial interests  RESEARCH PADRIC TO COUSTINATION PACHE MILES PARAMACCUTIONS, NOTER BLUCCA, BRANTA, CARBYSSANCE AFFANCE, BAYER, EDM. FYSERAM LA DAME, GARDANTA, DSP (42 AS A PERPORA E LESSANCE TO DAL MERE SED CHAPE IN THE ABSENCE OF LY POTOXIC THEMPY, ARE REST. AND Please summarize the above conflict of interest in the following box:  CONSULTING: ROCKE, CARGONE, CELLETTH, ATHAT ZENECA, SEATTLE GENETICS, GRICH: SHAMED, CRUTHER, ATHERDES, ROTE (14), 107), BEK, LECUKO, BOASS, CLOW On-CAUGH, BERTHER TANKING, CRUTHER, ATHERDES, ROTE (14), 107), BEK, LECUKO, BOASS, CLOW On-CAUGH, BERTHER TANKING, CRUTHER, ATHERDES, ROTE (14), 107), BEK, LECUKO, BOASS, CLOW On-CAUGH, BERTHER TANKING, CRUTHER, ATHERDES, ROTE (14), 107), BEK, LECUKO, BOASS, CLOW On-CAUGH, BERTHER TANKING, CRUTHER, ATHERDES, ROTE (14), 107), BEK, LECUKO, BOASS, CLOW On-CAUGH, BERTHER TANKING, CRUTHER, ATHERDES, ROTE (14), 107), BEK, LECUKO, BOASS, CLOW, SENTING THE ADDRESS OF MARINET AND TONE CARBONICS OF SENTING THE ADDRESS OF MARINET CARBONICS OF SENTING THE ADDRESS OF SENTING ACCOUNTY OF SENTING THE ADDRESS OF SENTING AND A RICADONESS OF SENTING ACCOUNTY OF SENTING THE ADDRESS OF SENTING AND A RICADONESS OF SENTING ACCOUNTY OF SENTING THE ADDRESS OF SENTING THE ADDR				
writing, gifts or other services  13 Other financial or non-financial interests  None  Non	12		<u></u> ✓ None	
Services  13 Other financial or non- financial interests  RESERVEY RUDING TO CONSTITUTOU. RECHE MIND PHARMACEUTIONS, NOTHA ZENECA, BANALTA, CANSYSVENIER AFFAIRS, BAYAR, EDING FYERFRAM CA RECHE, GENERAMONTO, DSP  MAR CONTS, CASTAN A REJANDO R. U.S. BINEVEZ, NOLETA SCRUA C'RI FALDE, WD 2014   199294 A 5358ED  PLEZ AS A PRIPATOR OF RESIDUE TO DIAL MERZ BLOCKARE IN THE MASENCE OF LY POTDXIC THERMY, AREA PROF. AND  PLEASE SUMMARIZE the above conflict of interest in the following box:  CONSULTING: RECHE, CAGGUE; CELLISTIA, ASTINA ZENECA, SENTLE GENETICS PAICH: SAMALYO, CRUTHEL, ATHERES, ROLPP  LLONGART, JANEN LATE  US 2019 0 338 36.8 A CL  CONSULTING: RECHE, CAGGUE; CELLISTIA, ASTINA ZENECA, SENTLE GENETICS PAICH: SAMALYO, CRUTHEL, ATHERES, ROLPP  LLONGART, JANEN LATE  CONSULTING: RECHE, CAGGUE; CELLISTIA, ASTINA ZENECA, SENTLE GENETICS PAICH: SAMALYO, CRUTHEL, ATHERES, ROLPP  LLONGART, JANEN LA CHECKE, SENTLE AND A CHECK SAMALYO, ASTINA ZENECA  FRANCE: ROLLE, NOTACTS, EISTA, REPUBLA, ASTINA ZENELA, PAICH SAMALYO, CILEA P  RATING: PHARMACEUTICAL CAGGUATION OF A PIKSCA INHIBITION AND A RICHE DEBUS DISTABILITANG AGAIN JENECATH  PROMISE SOURCE OF REPORTS TO PUAL MERZ BLOCKARG: IN THE ABSENCE OF REPORTORIC THEMPS  ROLL AND LLOLA, JENE CANAL USTOR O 338 368 A1 LICENSED  SOUR; NEDSTA, NETTRAPPARTITUS CONTRACTORS, LED PLANTAGUETUS, ASTINATURCA, BARALTA, CABIN SAMALA, PAICH PLANTAGUETUS, ASTINATURCA, BARALTA, CABIN SAMALA, PAICH PROMISE DISTABILITANO, BEYEN, PERSON PROMISE TO DESTRUCTURE, ASTINATURE, ASTINATURE, ASTINATURE, BARALTA, CABIN SAMALA, PAICH PROMISE DISTABILITANO, BEYEN, PAICH THE PLANTAGUETUS ASTINATURE, ASTINATU		1 10 10 10 10 10 10 10 10 10 10 10 10 10		
Other financial or non- financial interests  RESERVEL FRUING BO COUNTINGOU. REME PAIRS FRAMMACEUTIONS, ALTHA REMECA, BARKER CARRYSSENTER AFFANCE GAYER, EDIN, FYCHRAM LA REME, GURERANTA, DS.  MARKER CONTISCASTAR ALEJANDON C. LUS BENEVEZ, NOVETH SCRUAR CHE TALDE, WO ZON'L 1992 94 A TSSÉED  REZ AS A REXPLOR & RESONIE TO DAL MERZ BLOCKADE IN THE ABSENCE OF LY POTOXIC THEMAY, AREA PART AND  Please summarize the above conflict of interest in the following box:  CONSULTING: ROCKE, COLOURS, CELLETTHA, ATHAN ZENECA, SCRITTIK GENETICS, PANCH: TAMBURY, ACTUALLY, ROLLES, BLOVE, CLUY, NDP, BEK, LEUKO, BEDASS, CLON ON-CAUGHY, BOLBRINGER TAMBURY, HISTORY, ATHENEX, ROLLES, BLOVE, HISTORY, CLUGANI, SCRITTI, SANDONIO BIOCRESS, CLUY, NDP, DANCKI SANDAYO, CRUTACI, ATHAN ZENEC CAR  PRATICUS: PRABACHEUTICAL CORBINATION OF A PIKSCA INHIBITION AND A RICCASTUBUS DISTABLISHOW ACCUS JENECOM  PRATICUS: PRABACHEUTICAL CORBINATION OF A PIKSCA INHIBITION AND A RICCASTUBUS DISTABLISHOW ACCUS JENECOM  PRATICUS: PRABACHEUTICAL CORBINATION OF A PIKSCA INHIBITION AND A RICCASTUBUS DISTABLISHOW ACCUS JENECOM  PROSER PLACE OF REJONSE TO PURA MERZ BLOCKADO IN THE ABSENCE OF MITOTOXIC FIRMAN  PROSER AND LIGHT JENECOMES (TO DURA MERZ BLOCKADO IN THE ABSENCE OF MITOTOXIC FIRMAN  PROSER, NEDERIC, NEVERTHERMS, CENTER, DEUTED, LEUKO (TRELATE)  STOCK: MEDSTA, NEVERTHERMS, CENTER, DEUTED, LEUKO (TRELATE)  PLEASE PLACE OF MITOTOXIC PRABACHICALLY ASTANDANCA, BARALTA, GABIJ SANDA PLIPAL, PURA PRABACHICALLY ASTANDANCA, BARALTA, GABIJ SANDA PLIPAL, PURA PRABACHICAL ASTANDANCA, BARALTA, GABIJ SANDA PLIPAL PLIPAL PLACE PLA		A STATE OF THE STA		
financial interests  RESERVEY FROME TO COUNTINGOUS PERFORM LA PROMERCIANTS, NOTH RENECA,  BANALTA CONTINUES TO STATE APPARE, BAYER, EDIN, FREMAN LA POSTE, GUNGANTA, DSD  MER CONTINUES TO MALL METER SCOKEAR IN THE ABSENCE OF LY POTOXIC THEMAY. ALUR RUS AND  Please summarize the above conflict of interest in the following box:  CONSULTING: ROTHE, OLIGANE; CELLATIA, ASTINA FEDERA, SENTILL GENETICS, PRICH: SAMENO, CRUTHER, ATHEMEX, ROLPP  LLY, NSD, ESK, LEUKO, BOASS, CLON ON COLOGY, BOLPMANTE TOURISHING, EKERES, M. IS COLD, BO NOSI, COLOR ON COLOGY, BOLPMANTE TOURISHING, EKERES, M. IS COLD, BO NOSI, COLOR ON COLOGY, BOLPMANTE TOURISHING, EKERES, M. IS COLD, BO NOSI, COLOR ON COLOGY, BOLPMANTE TOURISHING, EKERES, M. IS COLD, BO NOSI, COLOR ON COLOGY, BOLPMANTE TOURISHING, EXPRES, M. IS COLD, BO NOSI, COLOR ON COLOGY, BOLPMANTE TOURISHING, CHURCH, ATHEMEX, ROLP,  KONDANA: RECHE, NOVATOS, CELLATIVE, EISH, PRATIS, SANDUNG BIOCRSS, CLLLY, NSD, ORIGINI SANDLYO, ASTINA FLUE A  PRANEL: BOLHE, NOVATOS, CELLATIVE, EISH, PRATIS, SANDUNG BIOCRSS, CLLLY, NSD, ORIGINI SANDLYO, ASTINA FLUE A  PRANEL: BOLHE, NOVATOS, CELLATIVE, EISH, PRATIS, SANDUNG BIOCRASIC, IN THE ABSENCE OF COLOTOXIC FINANCE  ALIGIDAD SING GIOLOGY, NOVER BUR ELIFOLISM, NOVATOR ON THE ABSENCE OF COLOTOXIC FINANCE  PROFILE AND LIBED A JURIE CANTER, USTOR 10338 368 AM LICENSED  STOLK: MEDSIN, NEXTREPHARMETURAND, COLDE, AND PRANTPENECA, BARALTA, CABIN SANDLAR, COLDE, AND PRANTPENECA, BARALTA, CABIN SANDLAR, PRANTPENECA,	********			
BARACTA CARBYSSINICE AFFAIRE, BAYER ETIM, FROFTMAN CA ROUTE, GENERANTA, DSP  MAGE CONTISCASTRIP ARE JANDE F. US GENEREZ, VIDLETA SCRUA CHE TALDE, WD 2014   19214 A JISCHED  REZ AS A PREPLIDA OF RESPONSE TO DUAL MERZ BLOCKADE IN THE ABSENCE OF LY DOTOXIC THERAPY. ARE PROT AND  Please summarize the above conflict of interest in the following box:  CONSULTING: Route, Calgoric, Cellotth, ASTIVA ZENECA, SEATTLE GENETICS PARICH: SANGGO, ETYTHER, ATHERIES, RELIGIO, INSTANCE, ASTIVA ZENECA, SEATTLE GENETICS PARICH: SANGGO, ETYTHER, ATHERIES, RELIGIO, INSTANCE, ASTIVA ZENECA, SEATTLE GENETICS PARICH: SANGGO, ETYTHER, ATHERIES, RELIGIO, INSTANCE, RECEIVE, RESPONSE, LECUXO, BOASIS, CLOW ON CALOGY, BOLDANDARICE TROUBLES, HISRAEL, BOLDANDARIA: RECEIVE, ETSA, PRICE, SANDONES SICEPSS, LILLY, NSD, DATICHI SANGGO, ASTIVA ZENECUA  TRAVEL: POLHE, NOTARTIS, ETSA, PRICE, ASTIVA ZENELA, PARICH: SANGGO, OS LEAD  PATINTS: PHARAREUTICAL CARBINATION OF A PIKSCA INHIBITION AND A DICARDORUS DOTABLICHOGA AGENT JENECOM  ALICIDAD PRICEDAD, POLICIPAL LOS POLICIPAL PROPRESENCE  PROTITO DESTITUTOR OF RESPONSE TO PUAL HERE BLOCKADO IN THE ABSENCE OF CITOTOXIC TRICTURE  RESPARCH RUTTURE TO DESTITUTOR. ROCHE, ASTIP PHARAPOLUTICAL, ASTIVATORICA, BARALTA, CABIT SENOR APPENDICA, BEYER, RIVERALLY PROPRESEDERALLY CONTROL TO DESTITUTORICA PARACTURALLY CONTROL TO INSTITUTORICA PARACTURALLY CONTROL TO INSTITUTORICA PARACTURALLY CONTROL TO INSTITUTORICA PARACTURALLY CONTROL CONTR	13	Other financial or non-		
BARACTA CARBYSSINICE AFFAIRE, BAYER ETIM, FROFTMAN CA ROUTE, GENERANTA, DSP  MAGE CONTISCASTRIP ARE JANDE F. US GENEREZ, VIDLETA SCRUA CHE TALDE, WD 2014   19214 A JISCHED  REZ AS A PREPLIDA OF RESPONSE TO DUAL MERZ BLOCKADE IN THE ABSENCE OF LY DOTOXIC THERAPY. ARE PROT AND  Please summarize the above conflict of interest in the following box:  CONSULTING: Route, Calgoric, Cellotth, ASTIVA ZENECA, SEATTLE GENETICS PARICH: SANGGO, ETYTHER, ATHERIES, RELIGIO, INSTANCE, ASTIVA ZENECA, SEATTLE GENETICS PARICH: SANGGO, ETYTHER, ATHERIES, RELIGIO, INSTANCE, ASTIVA ZENECA, SEATTLE GENETICS PARICH: SANGGO, ETYTHER, ATHERIES, RELIGIO, INSTANCE, RECEIVE, RESPONSE, LECUXO, BOASIS, CLOW ON CALOGY, BOLDANDARICE TROUBLES, HISRAEL, BOLDANDARIA: RECEIVE, ETSA, PRICE, SANDONES SICEPSS, LILLY, NSD, DATICHI SANGGO, ASTIVA ZENECUA  TRAVEL: POLHE, NOTARTIS, ETSA, PRICE, ASTIVA ZENELA, PARICH: SANGGO, OS LEAD  PATINTS: PHARAREUTICAL CARBINATION OF A PIKSCA INHIBITION AND A DICARDORUS DOTABLICHOGA AGENT JENECOM  ALICIDAD PRICEDAD, POLICIPAL LOS POLICIPAL PROPRESENCE  PROTITO DESTITUTOR OF RESPONSE TO PUAL HERE BLOCKADO IN THE ABSENCE OF CITOTOXIC TRICTURE  RESPARCH RUTTURE TO DESTITUTOR. ROCHE, ASTIP PHARAPOLUTICAL, ASTIVATORICA, BARALTA, CABIT SENOR APPENDICA, BEYER, RIVERALLY PROPRESEDERALLY CONTROL TO DESTITUTORICA PARACTURALLY CONTROL TO INSTITUTORICA PARACTURALLY CONTROL TO INSTITUTORICA PARACTURALLY CONTROL TO INSTITUTORICA PARACTURALLY CONTROL CONTR		financial interests	RESERVELY GRUDNIG TO CO	OUSTITUTION RECOVERANCE PHARMACEUTICAS, NOTICA ZENECA,
Please summarize the above conflict of interest in the following box:  Consulting: Roche, adjustic Cellotth, astric teneral, seattle Genetics, phich samely, register, atherest, lover ally, NSD, Box, teuro, Boass, and on-choogy, Boathmeter Ingellium, Ekeptes, Historia, Boass, a filed, nematic, typewardy, level general, expression significations, established, Books, and the colors, historia, sambune Biolosis, cilly, NSD, Dalichi samelyo, astric can the choracis. Exche, advants, citar, Ritar, sambune Biolosis, cilly, NSD, Dalichi samelyo, Astric can the choracis. Exche, advants, essa, proton, Astric, sambune Biolosis, cilly, NSD, Dalichi samelyo, Astric can the control of a pictoria, patient samelyo, astric both astriction and a nicronomic both both action and a protocom functions. Pharaceutical consideration of a pictoria in the source of a protocom place control and consideration of a pictoria, and and a nicronomic both both function and a pictoria and a nicronomic both both function and a pictoria and a nicronomic both both function and a pictoria and a nicronomic both function.  Prod. Andrew Control of as power to the following statement to indicate your agreement: washed. On from the Please place an "X" next to the following statement to indicate your agreement: washed. On from the Please place an "X" next to the following statement to indicate your agreement: washed.			BAUALTA LONGUS BRICE ASPA	HYEO, GAYER EDIA: FYGHRAM LA ROCKE, GUARDANTM, DSP, Y
Please summarize the above conflict of interest in the following box:  Consulting: Roche, algebre; Celletth, asther teneral, seattle Genetics, phich: samely, revented, atherest, Polype ally, NSP, Bek, Leuko, Boasis, and on-choogy, Boethmeter Ingelham, Ekeptes, Hiterally, Bonnet, College, Nonathi, Typewarder, Newel general, expression significations, Ekeptes, Hiterally, Bonnet, College, Novators, Celative, Fish, Prital, Sambonie Bioeps, Lilly, NSP, Dalichi samelyo, Astha Zene can provide Banker. Polype and a nicropolitis Bathalithus again fever can prival. Pharaceutical consideration of a piksca initistion and a nicropolitis Bathalithus again fever can place as a prelictor of response to public Blockage in the Absence of legioloxic Fithere was a polyper and content of the polyper and content place of the polyper place of the polyper place of the polyper place and content place of the polyper place of the polyper place and content place of the polyper place and content place of the polyper place and content of the polyper and content of th	WER	L COUTES CASTAN A LECTANDO PIL	IS BINENEZ MOLETA SCRUA	LYLITALDE, WO 2014 199284 A TISCHED
CONSULTING: Racke, algent; CELLISTIA, ASTMA ZENECA, SEATTLE GENETICS PARICH: SAMEYO, ETYTHER, ATHEREX, POLYPI  CILY, NDP, Box, LEUKO, BOASIS, CLOW Oncology, BOLAMANTE Inophlaim, EMPLES, HISTORY, COLOR  GILOLO, NENDAMI, EYREN STLEY, REVEL GENETICS, EXPRISZION SIGNIFICATION OF A PROPERTY.  HAUMANIA: ROCHE, ADVANTS, CELCTIVE, ETSA, PRITTA, SAMBUNG SIOLESS, CILLY, ND, DARICKI SANLYO, ASTMA ZENE UA  PRATTUS: PHARMACEUTICAL CONSINATION OF A PIKSCA INHIBITOR AND A NICOSTREUT DOTABILITHOG AGENT JENENCHA  PROTECTION SING GIALLEY, Noble ine Elifolds, UPO 20141 PG 294A: ITSUE?  HOLZ OS OF PHICTORY OF RESPONSE TO PUAL MERS BLOCKAGE IN THE ABSENCE OF GITOTOXIC FIRSTER  PROTECTION OF MEDSIA, NEWTAR/PHARMACEUTICAD, LEUKO (NEDERLE)  RESEARCH RUTHUS TO DISTITUDU. BOCKE, ARIAT PRANTIFICATION ASTMAZENECA, BARACTA, GABIN SENNE, AHENES, BEYEN, EINE  Please place an "X" next to the following statement to indicate your agreement: MARMACE, OF RESPONSE OF CIPUT THE	007	AS A PREDITION OF WEST ONLY	TO DIAL METZ BLOCKADE	IN THE ABSENCE OF IN DOTOXIC THERAPY. Alex PROT. Andone
CONSULTING: Rocke, algene; CELLOTTA, ASTALA ZENECA, SCATTLE GENETICS, PAICH: SAMELO, CRUTHER, ATHENEX, POLYPE  Lily, NDP, BEK, LEUKO, BIDASIS, CLONI On-COLOGY, BOLAMANICE TANGELLAMA, EKAPES, HISECALLA, BID MASH, G  GILOS, NOLOMANICE, PROCESS, CLOTINE, EISA, PRIMI, SAMBUNG BIDEPSS, LILLY, NDD, DAICHI SANKYO, ASTALA ZENECLA  PRANCE: POLHE, NOVACTIS, EISA, PRIMI, ASTALA ZENELA, PAICHI SANKYO, GILEAD  RATINIS: PHANACEUTICAL CONSINATION OF A PIKSCA INXI BETOR AND A NICHONORUS DOTABILITMO AGENT JENECOME  PROCESSOR CINSCONSON OF RESPONSE TO PUBL MERS BLOCKADO IN THE ABSENCE OF METOTOXIC HEKETAP  PROS. AND DELLOS, JUNE CONSEL USTOR 10338 368 AT LICENSED  STOLK: NEDSIR, NEXTAMPRARAMETUTICAN, LEUKO (NEDENIE)  RESEARCH FUNTING TO DISTITUTEN BOCKE, ASTAT PHANATRAUTICAN ASTALAZINCA, BARACTA, GABIT, SENIE, AHEAUS, BEYEN, EINE  Please place an "X" next to the following statement to indicate your agreement: Mash & 150 Right Pick of The	Ple	ease summarize the above	conflict of interest in the fo	llowing hox: LLOMBART, JAWER CATTES,
CONSDITING: ROTHER, EXCHERITION, HISTOR PERCHA, SENTITE GENETICS PARICHISTANCYO, ETUTHER, ATHENEX, POLYPE  LILY, NDP, BEK, LEUKO, BOASIS, CLON On-LOUGY, BOLHMINGE Inoglikim, EKIPTES, HISTORIA, GO LOUGH, ASTOR STUTIA, PARICHISTOR AND A RICHARDEUT BOTHBRITHNG AGENT JEVEN COME  PROTITUS: PHARACEUTICAL CONSINATION OF A PIKSCA INHIBITOR AND A RICHARDEUT BOTHBRITHNG AGENT JEVEN COME  PROJECTION GIVE GONZO, Nobele DUE FLIGHTA, LOUGH BOLLAGO IN THE ABSONCE OF LEGITOTOXIC FIRST PROSECULATION OF LOUGH LOUGH LOUGH CONTROLLED C				US 2019 10 220 200 AM C) CF
CITY, 188, 882, LECKE, BONSO, COSTO CACASOGY, BOLHMANTE INOPHIAM, EKIPTS, HISICAL, BIOTHER, GILER, ROTHER, BIOTHER, BONSON, CELOSING, PRINT, SANDING SICEPSU, LILLY, 180, DANICHI SANKYO, ASTRA ZENE LA TRAVEL: POLHE, NOMBOTS, EISA; PRICA, ASTRA ZENELA, PATICAI SANKYO, GILERA PRINTI: PHARAPEEUTICAL CONSINATION OF A PIKSCA INVIBITION AND A NICASTUBUS BOTABILITMO AGENT JENER CONTRATION OF A PIKSCA INVIBITION AND A NICASTUBUS BOTABILITMO AGENT JENER CONTRATION OF A PIKSCA INVIBITION AND A NICASTUBUS BOTABILITMO AGENT JENER CONTRATION OF A PIKSCA INVIBITION AND A NICASTUBUS BOTABILITMO AGENT JENER CONTRATION OF RESPONSE TO PUAL HERZ BLOCKADO IN THE ABSONCE OF LETOTOXIC FIENTAM PROSPECTORIO, LO LO LOS JUNCO (TOLE NIC)  STOLK: NEDSIR, NEXTANDAMENTO DE LOCALO, LOURO (TOLE NIC)  RESTARLIT FUNTANO TO DESTITUTO: BOCKE, ASTRATOROLITICAL ASTRATORICA, BARACTA, GABRI SENNE, AHERUS, BEYER, EIGER PLACER ON THE PROSPECTORIO SEVEN, BUTCH OF THE PLACER OF STOLE THE PROSPECTORIO SEVEN, ASTRATORIOLOLICAL ASTRATORICA, BARACTA, GABRI SENNE, AHERUS, BEYER, EIGER PLACER ON THE PROSPECTORIOLOGICAL PROPERTICAL ASTRATORICA, BARACTA, GABRI SENNE, AFRONCE, BEYER, EIGER THERE	0	DNSULTING: ROCHE, COLGENE,	CELLISTIA, ASTAVA ZENECA, SE	ATTLE CIT VEDOS BASICUS FAMILIES FOLLOWING A TO I WOUND
HOLDRAMA: ROCHE, NOVADTS, LESA, PRITA, SANDUNG SIDERS, LILLY, NSD, DAIGNI SANDYD, ASTNA ZENE LA  TRAVEL: POLHE, NOVADTS, LISA, PRITA, ASTRA ZENERA, DAIGNI SANDYD, GILEAD  PATINTS: PHARMACEUTICAL CONSINATION OF A PIKSCA INVIBITION AND A NICOSTUBUL DETABLITHUG AGENT JENER CONTRACTOR PROJECTOR CITUS GIALDE, NOVER DE ELIFOLDO, NO 2014 199294A: ISSNED  HOLZ OS OF PUBLICHOR OF RESPONSE TO PUBL HERZ BLOCKADO IN THE ABSONCE OF COTOTOXIC FICKING PROJECTOR IN THE ABSONCE OF COTOTOXIC FICKING STOCK: NEDSIR, NEXTREPHARMACEUTICAD, LEDIKO (RELEADE)  STOCK: NEDSIR, NEXTREPHARMACEUTICAD, LEDIKO (RELEADE)  RESTARLIT FUTURG TO DISTITUTED. ROCHE, ASTAD PRANTACUTICAD, ASTNATURICA, BARACTA, GABIN SENNE, ATHRAUS, BEYEN, EIGHT THERE		uly, ND, sox	, teuco, Bio Asis, classis danced	Logy, BOLAMINETE Ingelheim, EKIPITS, H. Jercell, Bio Mast, Gen
PRIORIE POLICE ROCKE, NOTATIS, EISA: PRICTO, ASTRA ZIVERA, PATICA'S SANTYO, GILLAD  PATINIS: PHARMACEUTICAL CONSINATION OF A PIKSCA INNIBITOR AND A RICHARDEUT BOTABILITMS AGENT JEVER CARRY  ALGICANO SINUS GIALLEY, VIOLENE EME ELIFELIS, WO CO 141 149 294A: IDINED  HOLZ OS O PROLICTOR OF RESPONSE TO PUAL MERZ BLOCKADO IN THE ABSENCE OF GITOTOXIC FICKITH  PROLITANO LLOLLON, JEVIN CONTR. USZOR 10338 368 AN CICENSED  STOCK: NEDSIR, NEXTREPHARMACEUTICAN, LEVINO (RELEXIE)  RESTARCH FURNIS TO DUSTITUTEN ROCHE, ARIAD PHARMACEUTICAN, ASTRAZONICA, BARACTA, GABRI SENNE, AFRONS, BEYEN, ENPERIENCE ON THE PLANTACUTICAN ASTRAZONICA, BARACTA, GABRI SENNE, AFRONS, BEYEN, ENPERIENCE ON THE PLEASE PLACE ON THE PROLITAGE OF THE PRO		Gilese, nersin	: I zyeew sites, devel gen-c	1, expression big the chologis,
PRIORIE POLICE ROCKE, NOTATIS, EISA: PRICTO, ASTRA ZIVERA, PATICA'S SANTYO, GILLAD  PATINIS: PHARMACEUTICAL CONSINATION OF A PIKSCA INNIBITOR AND A RICHARDEUT BOTABILITMS AGENT JEVER CARRY  ALGICANO SINUS GIALLEY, VIOLENE EME ELIFELIS, WO CO 141 149 294A: IDINED  HOLZ OS O PROLICTOR OF RESPONSE TO PUAL MERZ BLOCKADO IN THE ABSENCE OF GITOTOXIC FICKITH  PROLITANO LLOLLON, JEVIN CONTR. USZOR 10338 368 AN CICENSED  STOCK: NEDSIR, NEXTREPHARMACEUTICAN, LEVINO (RELEXIE)  RESTARCH FURNIS TO DUSTITUTEN ROCHE, ARIAD PHARMACEUTICAN, ASTRAZONICA, BARACTA, GABRI SENNE, AFRONS, BEYEN, ENPERIENCE ON THE PLANTACUTICAN ASTRAZONICA, BARACTA, GABRI SENNE, AFRONS, BEYEN, ENPERIENCE ON THE PLEASE PLACE ON THE PROLITAGE OF THE PRO	H	HONDRADIA: ROCHE, NOVAROIS, CELL	SENE, ETSAT, PRIZED, SANDUNG B	SIDE PSUS, LILLY, AS D, DATICAL SANKYO, ASTRUA ZENE LA
PATING: PHAGRACEUTICAL CONSINATION OF A PIXSCA INHIBITION AND A DICAGOUSTIES DISTABILITIES MEDICAL STRUCTURE MEDICAL CONSINATION OF A PIXSCA INHIBITION AND A DICAGOUST DISTABLE DISTABLE OF CONTROL HERE BLOCKADE IN THE ASSENCE OF CONTROL HERET PROS. AND IN NEXT CONTROL USPOR 10338 368 AT LICENSED  STOCK: NEDSTR, NEXT AND PROSTRED TO DISTITUTE SOCIETY AND PHARTICAL ASTRACTICAL				
HERE as a Predictor of response TO PUAL HERE BLOCKADE IN THE ABSENCE OF GITOTOXIC HEREITE  Pred Andrew Clastan, Jewie Conter USZOR 10338368 AT CICENSED  STOCK: NEDSIR, NEXTREPHARMENT COUNTRAD, LEVING (RELEADE)  RESEARCH FUTURE TO INSTITUTED BOCHE, ASTAT PHARMENT CAUS ASTAZZONICA, BARACTA, GABRI SENNE, Affence, Beyen, EISPER PLANER FOR AN PRESENCE ASTAZZONICA, BARACTA, GABRI SENNE, Affence, Beyen, EISPER PLANER FOR THE PROPERTY OF THE PROPERTY	0	MONTH OUARNACEUTICAL CON	BINATION OF A PIKSCA INHI	BITOM AND A DICK-RUBUL DETABLETING MODER O
PROS. AND TO LIGHT SOUTH COLLEGE ASTAR PRANTICAL ASTARTINGA, GABAJ SOUTH AND PROSECUTION OF RESPONSE TO PRANTICAL LEURO (RELEASE)  RESEARCH FUTURE TO DUSTITUTED. ROCHE, ASTAR PRANTICALLY ASTARTINGA, BARACTA, GABAJ SOUTH AHORUS, BEYEN, EVER  Please place an "X" next to the following statement to indicate your agreement: mandade 0.50 Roch Print Then	4	Alejado Pinis Gines	, Notete bue Flitolde, wo	2014/199294A: ISSUED
STOCK: NEDER, NEXTARPHARMEUTICAD, LEURO (NOLETAR)  RESTARCH FUTURE TO DUSTITUTOUS ROCHE, ASTRACTICALLY ASTRACTURAS, BARACTA, GABIN SERVE Affects, Bayer, Live  Please place an "X" next to the following statement to indicate your agreement: (mandous, 0.50 of the Office		Herz as a Predictor.	of assponse to pual here	2 BLOCKAGE IN THE ABSENCE OF ESTOLOXIC FEICH . 1.
Please place an "X" next to the following statement to indicate your agreement: manda & OSD Gran Piful Title		Pact And a Clarket	Live Confer USZORIAZ	38368 AL LIGENSED
Please place an "X" next to the following statement to indicate your agreement: manda & OSD Gran Piful Title	-	STOCK: NEDSIR, NEXTAR PPLACE	MACEUTICAL, LEUKO (NeleN	(2)
	20	TARIN CIATIVIS OF TATION	1. One Ha DO: DO DUDO DOS 1=11	a: A STA AZONICCA RAPATA COBBI SENILI AHENES, BUYER, CISTI)
	Ple	ease place an "X" next to th	e following statement to ir	ndicate your agreement: شعرف کم روده که کور و الای کا
		and the second of the second	121 102 103	person traper of the person of